Close Menu

Invitae

The nationwide study will enroll prostate cancer patients who do and don't meet current guidelines and assess how access to genetic information impacts their care. 

Natera previously filed infringement lawsuits against ArcherDx around four other patents related to cell-free DNA detection in oncology.

The firm generated $46.2 million in revenues compared to $53.5 million in the prior year, which was better than analysts' estimate of $39.6 million.

The index significantly outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in July.

The next iteration of Ancestry's Health experience seeks to provide customers with actionable information about certain commonly inherited health conditions.

The GenomeWeb Index rose more than 2 percent in June, but the increase was subdued compared to the index's 9 percent climb in May and 18 percent hike in April.

By combining with ArcherDX, Invitae will gain tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response.

The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.

Data presented at ACMG's online annual meeting suggests that more than 10 percent of prostate cancer patients across disease stages carry inherited cancer-related variants.

The available data suggests PGx may be useful in managing medications for COVID-19 patients and in helping people struggling with the mental health impact of the pandemic.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.